Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific ...
Le Lézard

Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight

DelveInsight's Ulcerative Colitis Market Insights report includes a comprehensive understanding of current treatment practices, ulcerative colitis emerging drugs, market share of individual therapies, ...
BioSpace

6 Biotechs That Could Be Big Pharma’s Next M&A Target

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...
sharewise

3 AI Stocks Showing Strong Momentum Heading Into 2026

As 2026 approaches, it’s prudent for investors to choose stocks that are charged up for big gains. In that context, investors ...